On the contrary, a meta-analysis, including 15 randomized clinical trials (712 patients) and 4 cohort studies (818 patients), found a reduction in mortality rates with IgM-enriched immunoglobulin for sepsis (Risk Ratio 0.60; 95%CI 0.52–0.69). The gene discussed is CD40LG; the disease is Sepsis.